Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC
NCT07777822
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with pembrolizumab and platinum-based chemotherapy doublet compared to placebo in combination with pembrolizumab and platinum-based chemotherapy doublet.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- NSCLC
- Non-small Cell Lung Cancer
- Non-Small Cell Lung Cancer NSCLC
- Non-Squamous Non Small Cell Lung Cancer
- Lung Cancer (NSCLC)
- Metastatic NSCLC - Non-Small Cell Lung Cancer
- Metastatic Non-Squamous Non-Small Cell Lung Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Revolution Medicines, Inc.
- Last updated on ClinicalTrials.gov
- August 20, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 1
- Florida Clinical Trials Group, LLC · Plantation, FL
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.